Table 2.
Summary of patient characteristics and treatment outcomes in haemophilic patients with chronic HCV infection treated with DAAs
| Patient No. | Age | Haemophilia | Severity | Genotype | F3/F4 | IFN | DAA | Duration, weeks | SVR 12 weeks |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 48 | A | Severe | 1a | − | ✓ | SOF/LDV | 12 | ✓ |
| 2 | 72 | A | Mild | − | ✓ | ✓ | SOF/LDV | 12 | ✓ |
| 3 | 53 | A | Mild | 1b | ✓ | − | SOF/LDV | 12 | ✓ |
| 4 | 49 | A | Severe | 1a | − | ✓ | SOF/LDV | 12 | ✓ |
| 5 | 47 | B | Mild | 1b | − | ✓ | SOF/LDV | 12 | ✓ |
| 6 | 43 | A | Moderate | 1a | − | ✓ | SOF/LDV | 12 | ✓ |
| 7 | 72 | A | Moderate | 1a | − | ✓ | SOF/LDV | 12 | ✓ |
| 8 | 57 | A | Severe | 1a | ✓ | − | OBV/PTV/r+DSV | 12 | ✓ |
| 9 | 54 | A | Severe | 1b | ✓ | ✓ | SOF/LDV+RBV | 24 | ✓ |
| 10 | 59 | A | Moderate | 1b | ✓ | ✓ | SOF/LDV | 24 | ✓ |
| 11 | 51 | A | Mild | 3a | ✓ | ✓ | SOF/LDV | 24 | ✓ |
| 12 | 43 | A | Moderate | 1a | − | ✓ | SOF/LDV | 12 | ✓ |
| 13 | 81 | A | Mild | 1b | ✓ | ✓ | EBR/GRZ | 12 | ✓ |
| 14 | 56 | A | Moderate | 2 | ✓ | ✓ | SOF+RBV | 16 | ✓ |
| 15 | 63 | A | Mild | 1b | ✓ | ✓ | SOF/LDV | 24 | ✓ |
| 16 | 39 | A | Severe | 1b | ✓ | ✓ | SOF/LDV | 12 | ✓ |
HCV, hepatitis C virus; DAA, direct-acting antiviral; DSV, dasabuvir; EBR, elbasvir; GRZ, grazoprevir; F3/F4, fibrosis stage 3 or 4 (advanced liver disease); IFN, interferon experienced; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response.